Login to Your Account



Concert Sings 'All That Jazz' With D-SXB Licensing Deal

By Marie Powers
Staff Writer

Wednesday, February 27, 2013
deals_and_ma.jpg

Privately held Concert Pharmaceuticals Inc. struck another business development high note, inking an exclusive license agreement that provides Jazz Pharmaceuticals plc with global rights to develop and commercialize deuterium-modified sodium oxybate (D-SXB) compounds, including C-10323, aimed at narcolepsy.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription